The amount of revenue arising from transactions involving the Company's medicines as well as medicine the Company has acquired an interest in. Such income included upfront consideration, milestones receipts and royalties, as well as other income from collaborations.

No definition available.

Name:	azn_CollaborationRevenue
Namespace Prefix:	azn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaboration Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Collaboration Revenue (Details) - USD ($) $ in Millions	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenues
Total collaboration revenue	$ 8	$ 4	$ 82	$ 49
Other Collaboration Revenue
Revenues
Total collaboration revenue			5
Farxiga: sales milestones
Revenues
Total collaboration revenue			$ 77	$ 49